Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated just now
PreprintAll rights reservedbioRxiv

Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition

  • M. P. East
  • J. F. Olivares-Quintero
  • D. O. Okumu
  • K. R. Mott
  • R. W. Sprung
  • A. A. Whitman
  • C. U. Joisa
  • X. Chen
  • Q. Zhang
  • P. Erdmann-Gilmore
  • Y. Mi
  • J. P. Malone
16 more authors
  • S. Bhatia
  • I. C. McCabe
  • Y. Xu
  • M. D. Sutcliffe
  • P. A. Spears
  • J. S. Zawistowski
  • C. M. Perou
  • H. S. Earp
  • L. A. Carey
  • J. J. Yeh
  • D. L. Spector
  • D. Stover
  • S. M. Gomez
  • P. M. Spanheimer
  • R. R. Townsend
  • G. L. Johnson1
  1. 1University of North Carolina at Chapel Hill
Read full textPDFDOICite

Related

  1. A therapeutic vulnerability linking MNK1/2 inhibition and G1/S cyclin-dependent kinase blockade in triple-negative breast cancer
    Q. Deng, M. Amiri, A. Moshari +11
    bioRxivPreprintCC BYFull textOncologybioRxiv
  2. Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor beta-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer
    Chetan C Oturkar, Junhoung Park J, Iqbal Ijaz +21
    bioRxivPreprintAll rights reservedFull textOncologybioRxivPMC
  3. Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancers
    Sarah Cogoluegnes, Sandra Kovachka, Thierry Dubois +7
    Translational OncologyPeer-reviewedCC BY 4.0Full textProteomics & metabolomicsGeneral biologyHAL
  4. SCD1 inhibition promotes lipid peroxidation and enhances anti-PD-1 response in triple-negative breast cancer
    Quentin Herrera Garfia, Aurélien Azam, Eric Bonneil +5
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyPMCCrossrefEurope PMC
  5. Benefits and adverse events of combined chemotherapy and immune checkpoint inhibition in non-metastatic triple-negative breast cancer: a systematic review and an updated meta-analysis
    Jianmin Wu, Kejing Zhang
    Translational Breast Cancer ResearchPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC

Cite

BibTeXRIS
BibTeX
@misc{east2026vulnerability,
  title = {{Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition}},
  author = {M. P. East and J. F. Olivares-Quintero and D. O. Okumu and K. R. Mott and R. W. Sprung and A. A. Whitman and C. U. Joisa and X. Chen and Q. Zhang and P. Erdmann-Gilmore and Y. Mi and J. P. Malone and S. Bhatia and I. C. McCabe and Y. Xu and M. D. Sutcliffe and P. A. Spears and J. S. Zawistowski and C. M. Perou and H. S. Earp and L. A. Carey and J. J. Yeh and D. L. Spector and D. Stover and S. M. Gomez and P. M. Spanheimer and R. R. Townsend and G. L. Johnson},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.16.752096},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.16.752096v1},
}
RIS
TY  - UNPB
TI  - Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition
AU  - M. P. East
AU  - J. F. Olivares-Quintero
AU  - D. O. Okumu
AU  - K. R. Mott
AU  - R. W. Sprung
AU  - A. A. Whitman
AU  - C. U. Joisa
AU  - X. Chen
AU  - Q. Zhang
AU  - P. Erdmann-Gilmore
AU  - Y. Mi
AU  - J. P. Malone
AU  - S. Bhatia
AU  - I. C. McCabe
AU  - Y. Xu
AU  - M. D. Sutcliffe
AU  - P. A. Spears
AU  - J. S. Zawistowski
AU  - C. M. Perou
AU  - H. S. Earp
AU  - L. A. Carey
AU  - J. J. Yeh
AU  - D. L. Spector
AU  - D. Stover
AU  - S. M. Gomez
AU  - P. M. Spanheimer
AU  - R. R. Townsend
AU  - G. L. Johnson
PY  - 2026
DA  - 2026/09/16
PB  - bioRxiv
DO  - 10.64898/2026.09.16.752096
UR  - https://www.biorxiv.org/content/10.64898/2026.09.16.752096v1
ER  -